AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter ...

Its lead product candidate is LIVMARLI (maralixibat), an orally administered ... treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Mirum's $400,000-a-year oral drug Livmarli, or maralixibat, was approved in September 2021 to treat Alagille syndrome, a condition that includes persistent itch and a variety of heart and bone issues.

The company’s lead product, Livmarli (maralixibat), has been a key driver ... which is approved for Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC).

Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941] Technology appraisal guidance TBC Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312 ...

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043] Technology appraisal guidance TBC Maralixibat for treating cholestatic pruritus in Alagille ...

Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution ... of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe ...

Mirum has three approved medications: LIVMARLI ® (maralixibat ... the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe ...

LIVMARLI® (maralixibat) oral solution is an orally administered ... It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age ...